ArticleGland surgery2025
A predictive model using platelets and neutrophil-to-lymphocyte ratio for the number of lymph node metastases in papillary thyroid carcinoma: a retrospective analysis.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic factors for survival and recurrence in papillary thyroid carcinoma: a retrospective study.Gland surgery · 2025Article
- Assessing the Role of Inflammatory Markers in Predicting Central Lymph Node Metastasis in Papillary Thyroid Carcinoma.Iranian journal of otorhinolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Large number lymph node metastases (LNLNMs) in papillary thyroid carcinoma (PTC) significantly increase recurrence risk, yet preoperative prediction remains challenging. This study aimed to develop a predictive model integrating blood inflammatory markers and clinical features to identify patients with high-risk LNLNM. Methods: A retrospective cohort of 731 patients with PTC who underwent thyroid surgery at Hangzhou First People's Hospital between September 2021 and October 2022 was included. These patients were divided into a model group (n=513) and a validation group (n=218) at a 7:3 ratio. Analyzed variables included age, gender, absolute values of neutrophils (N), monocytes (M), platelets (Plt), and lymphocytes (L), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammatory index (SII), and tumor diameter and multifocality. Independent risk factors for LNLNM were identified through univariate and multivariate logistic regression analyses, and a risk prediction model was subsequently constructed. Model performance was assessed via receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow (HL) test, calibration curves, and decision curve analysis (DCA). Results: Age, tumor diameter, Plt, and NLR were identified as independent risk factors for LNLNM in patients with PTC. A predictive model was developed to evaluate the risk of LNLNM, with an area under the curve (AUC) of 0.827 (95% CI: 0.784-0.870; P<0.001) and the specificity and sensitivity were both 75.8%. The AUC of the validation group was 0.824 (95% CI: 0.757-0.890; P<0.001), with a specificity of 79.5% and a sensitivity of 76.9%. Furthermore, the model demonstrated good calibration in the HL test and favorable diagnostic value in calibration curve analysis and DCA. Conclusions: Age, tumor diameter, Plt count, and NLR count are high-risk factors for LNLNM in patients with PTC, and the predictive model established in combination with the above factors could effectively predict the occurrence of LNLNMs in PTC. This study provides support for surgeons in accurately predicting the possibility of LNLNMs and developing personalized treatment plans before surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.